Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting BCMA on malignant plasma cells. Upon BCMA binding, the CAR delivers activation and costimulatory signals, driving T‑cell activation, expansion, cytokine release, and perforin/granzyme‑mediated cytotoxicity to eliminate BCMA‑expressing myeloma cells.